Lorigerlimab

Phase 2Monoclonal antibody

MMacroGenics

Lorigerlimab is one of 117 biologic programs targeting Metastatic Colorectal Cancer. It is currently in Phase 2.

Indications

Total Trials

Active Trials

116

Competitors

Pipeline

Status by Indication[3][1]

Indication

Metastatic Colorectal CancerActive, not recruiting

Colorectal CancerActive, not recruiting

Prostate CancerActive, not recruiting

Cervical CancerActive, not recruiting

Metastatic Colorectal CancerPhase 1/Phase 2

Active, not recruiting

Colorectal CancerPhase 2

Active, not recruiting

Prostate CancerPhase 2

Active, not recruiting

Cervical CancerPhase 2

Active, not recruiting

Competition

Competitive Landscape

1399 competitors in Prostate Cancer

#DrugCompanyPhaseTrials

Lorigerlimab

MMacroGenics

Phase 2

1 2

Trexall

Alnylam Pharmaceuticals

Preclinical

—3

Jatenzo

GGrupo Espanol de Tumores Neuroendocrinos

Preclinical

2 4

Viagra

VViatris Specialty LLC

Preclinical

1 5

Duragesic

CCephalon

Preclinical

1 6

Ranexa

MMenarini International Operations Luxembourg SA

Preclinical

1 7

Prednisone/prednisolone

Roche

Preclinical

3 8

Osmitrol

BB. Braun Medical Inc.

Preclinical

—9

Ifex

BBaxter Healthcare Corporation

Preclinical

—10

Precedex

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

Phase 2Recruiting

Advanced Solid Tumors

NCT06730347

Clinical

Trials by Indication[1]

Advanced Solid Tumors2 trials

A Study of Lorigerlimab in Participants With Advanced Solid Tumors

Recruiting·MMacroGenics·Phase 2·NCT06730347·60 enrolled

A Study of MGC018 in Combination With MGD019 in Participants With Advanced Solid Tumors

Completed·MMacroGenics·Phase 1·NCT05293496·31 enrolled

Metastatic Cancer1 trial

MGD019 DART® Protein in Unresectable/Metastatic Cancer

Completed·MMacroGenics·Phase 1·NCT03761017·162 enrolled

Prostate Cancer1 trial

A Study of Lorigerlimab With Docetaxel or Docetaxel Alone in Participants With Metastatic Castration-Resistant Prostate Cancer

Active, not recruiting·MMacroGenics·Phase 2·NCT05848011·154 enrolled

Cervical Cancer1 trial

Triage of Advanced Cervical Cancer Through Immunotherapy Induction (TRACTION)

Recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT05475171·40 enrolled

Rectal Cancer1 trial

A Trial of Regorafenib Plus Lorigerlimab in Patients With Locally Recurrent or Regrowing pMMR/MSS Localized Rectal Cancer

Withdrawn·MM.D. Anderson Cancer Center·Phase 2·NCT07223567

2 more indications

Colorectal Cancer1 trial

Regorafenib (Reg) and Lorigerlimab (Lor), RELO Regimen, in Treatment of High-risk Patients With Colorectal Cancer With Radiographic Occult Molecular Residual Disease After End of Established Definitive Therapy [ReLOAD Trial]

Suspended·MM.D. Anderson Cancer Center·Phase 2·NCT07071961·16 enrolled

Metastatic Colorectal Cancer1 trial

A Trial of Regorafenib Plus Lorigerlimab as Neoadjuvant Therapy for Patients With pMMR/MSS, Resectable, Lung-limited Metastatic Colorectal Cancer

Withdrawn·MM.D. Anderson Cancer Center·Phase 1/2·NCT07137390

Sources

References

[1]
ClinicalTrials.gov — 8 trial records for Lorigerlimab. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Lorigerlimab compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Lorigerlimab. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — MacroGenics company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Monoclonal antibody[2]
Highest Phase: Phase 2[1]
Company: MMacroGenics

Lorigerlimab

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2027

Trials by Indication[1]

Advanced Solid Tumors2 trials

Metastatic Cancer1 trial

Prostate Cancer1 trial

Cervical Cancer1 trial

Rectal Cancer1 trial

Colorectal Cancer1 trial

Metastatic Colorectal Cancer1 trial

References

Drug Info

Quick Facts

Related News